Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease

L. Brusa, F. Petta, A. Pisani, V. Moschella, C. Iani, P. Stanzione, R. Miano, E. Finazzi-Agrò

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

OBJECTIVE: To compare acute and chronic effects of l-dopa on bladder function in levodopa-naive Parkinson disease (PD) patients who had urinary urgency. METHODS: We evaluated 26 l-dopa-naive PD patients at a university-based PD center with a first urodynamic session with a double examination: in the off treatment condition and 1 hour after acute challenge with carbidopa/l-dopa 50/200 mg; then, a chronic l-dopa monotherapy was administered (mean dose 300 ± 150 mg). Two months later, patients underwent a second urodynamic session with a single evaluation 1 hour after the acute carbidopa/l-dopa challenge. RESULTS: The first acute l-dopa challenge significantly worsened bladder overactivity (neurogenic overactive detrusor contractions threshold [NDOC-t; 32% of worsening] and bladder capacity [BC; 22% of worsening]); on the contrary, l-dopa challenge during chronic administration ameliorated the first sensation of bladder filling (FS; 120% of improvement), NDOCT-t (93% improvement), and BC (33% of improvement) vs the values obtained with acute administration. An 86% significant improvement of FS in comparison with the basal value was observed. CONCLUSIONS: The acute and chronic l-dopa effects may be due to the different synaptic concentrations or to the activation of postsynaptic mechanisms obtained by chronic administration.

Original languageEnglish
Pages (from-to)1455-1459
Number of pages5
JournalNeurology
Volume68
Issue number18
DOIs
Publication statusPublished - May 2007

Fingerprint

Dihydroxyphenylalanine
Parkinson Disease
Urinary Bladder
Carbidopa
Urodynamics
Overactive Urinary Bladder
Neurogenic Urinary Bladder
Levodopa

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Brusa, L., Petta, F., Pisani, A., Moschella, V., Iani, C., Stanzione, P., ... Finazzi-Agrò, E. (2007). Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology, 68(18), 1455-1459. https://doi.org/10.1212/01.wnl.0000260605.12506.86

Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. / Brusa, L.; Petta, F.; Pisani, A.; Moschella, V.; Iani, C.; Stanzione, P.; Miano, R.; Finazzi-Agrò, E.

In: Neurology, Vol. 68, No. 18, 05.2007, p. 1455-1459.

Research output: Contribution to journalArticle

Brusa, L, Petta, F, Pisani, A, Moschella, V, Iani, C, Stanzione, P, Miano, R & Finazzi-Agrò, E 2007, 'Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease', Neurology, vol. 68, no. 18, pp. 1455-1459. https://doi.org/10.1212/01.wnl.0000260605.12506.86
Brusa, L. ; Petta, F. ; Pisani, A. ; Moschella, V. ; Iani, C. ; Stanzione, P. ; Miano, R. ; Finazzi-Agrò, E. / Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. In: Neurology. 2007 ; Vol. 68, No. 18. pp. 1455-1459.
@article{c87d62b10dcd42f8b774906f1224e81c,
title = "Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease",
abstract = "OBJECTIVE: To compare acute and chronic effects of l-dopa on bladder function in levodopa-naive Parkinson disease (PD) patients who had urinary urgency. METHODS: We evaluated 26 l-dopa-naive PD patients at a university-based PD center with a first urodynamic session with a double examination: in the off treatment condition and 1 hour after acute challenge with carbidopa/l-dopa 50/200 mg; then, a chronic l-dopa monotherapy was administered (mean dose 300 ± 150 mg). Two months later, patients underwent a second urodynamic session with a single evaluation 1 hour after the acute carbidopa/l-dopa challenge. RESULTS: The first acute l-dopa challenge significantly worsened bladder overactivity (neurogenic overactive detrusor contractions threshold [NDOC-t; 32{\%} of worsening] and bladder capacity [BC; 22{\%} of worsening]); on the contrary, l-dopa challenge during chronic administration ameliorated the first sensation of bladder filling (FS; 120{\%} of improvement), NDOCT-t (93{\%} improvement), and BC (33{\%} of improvement) vs the values obtained with acute administration. An 86{\%} significant improvement of FS in comparison with the basal value was observed. CONCLUSIONS: The acute and chronic l-dopa effects may be due to the different synaptic concentrations or to the activation of postsynaptic mechanisms obtained by chronic administration.",
author = "L. Brusa and F. Petta and A. Pisani and V. Moschella and C. Iani and P. Stanzione and R. Miano and E. Finazzi-Agr{\`o}",
year = "2007",
month = "5",
doi = "10.1212/01.wnl.0000260605.12506.86",
language = "English",
volume = "68",
pages = "1455--1459",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "18",

}

TY - JOUR

T1 - Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease

AU - Brusa, L.

AU - Petta, F.

AU - Pisani, A.

AU - Moschella, V.

AU - Iani, C.

AU - Stanzione, P.

AU - Miano, R.

AU - Finazzi-Agrò, E.

PY - 2007/5

Y1 - 2007/5

N2 - OBJECTIVE: To compare acute and chronic effects of l-dopa on bladder function in levodopa-naive Parkinson disease (PD) patients who had urinary urgency. METHODS: We evaluated 26 l-dopa-naive PD patients at a university-based PD center with a first urodynamic session with a double examination: in the off treatment condition and 1 hour after acute challenge with carbidopa/l-dopa 50/200 mg; then, a chronic l-dopa monotherapy was administered (mean dose 300 ± 150 mg). Two months later, patients underwent a second urodynamic session with a single evaluation 1 hour after the acute carbidopa/l-dopa challenge. RESULTS: The first acute l-dopa challenge significantly worsened bladder overactivity (neurogenic overactive detrusor contractions threshold [NDOC-t; 32% of worsening] and bladder capacity [BC; 22% of worsening]); on the contrary, l-dopa challenge during chronic administration ameliorated the first sensation of bladder filling (FS; 120% of improvement), NDOCT-t (93% improvement), and BC (33% of improvement) vs the values obtained with acute administration. An 86% significant improvement of FS in comparison with the basal value was observed. CONCLUSIONS: The acute and chronic l-dopa effects may be due to the different synaptic concentrations or to the activation of postsynaptic mechanisms obtained by chronic administration.

AB - OBJECTIVE: To compare acute and chronic effects of l-dopa on bladder function in levodopa-naive Parkinson disease (PD) patients who had urinary urgency. METHODS: We evaluated 26 l-dopa-naive PD patients at a university-based PD center with a first urodynamic session with a double examination: in the off treatment condition and 1 hour after acute challenge with carbidopa/l-dopa 50/200 mg; then, a chronic l-dopa monotherapy was administered (mean dose 300 ± 150 mg). Two months later, patients underwent a second urodynamic session with a single evaluation 1 hour after the acute carbidopa/l-dopa challenge. RESULTS: The first acute l-dopa challenge significantly worsened bladder overactivity (neurogenic overactive detrusor contractions threshold [NDOC-t; 32% of worsening] and bladder capacity [BC; 22% of worsening]); on the contrary, l-dopa challenge during chronic administration ameliorated the first sensation of bladder filling (FS; 120% of improvement), NDOCT-t (93% improvement), and BC (33% of improvement) vs the values obtained with acute administration. An 86% significant improvement of FS in comparison with the basal value was observed. CONCLUSIONS: The acute and chronic l-dopa effects may be due to the different synaptic concentrations or to the activation of postsynaptic mechanisms obtained by chronic administration.

UR - http://www.scopus.com/inward/record.url?scp=34247612499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247612499&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000260605.12506.86

DO - 10.1212/01.wnl.0000260605.12506.86

M3 - Article

C2 - 17470746

AN - SCOPUS:34247612499

VL - 68

SP - 1455

EP - 1459

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 18

ER -